Nuvation Bio Announces Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated in the United Kingdom
Nuvation Bio announced that the UK Medicines and Healthcare products Regulatory Agency has validated the Marketing Authorisation Application for taletrectinib, submitted by partner Eisai, for advanced ROS1-positive non-small cell lung cancer. The application utilizes the International Recognition Procedure and is based on data from the pivotal Phase 2 TRUST-I and TRUST-II studies, targeting a UK market with approximately 50,200 new lung cancer cases annually.
Key figures
- Drug Name
- taletrectinib
- Phase Of Trial
- Phase 2
- Trust i participants
- 173
- Trust ii participants
- 189
- Uk annual lung cancer cases
- 50200
- Ros1 positive nsclc prevalence
- 2%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.